Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE reported a notable 13% year-over-year increase in product sales, reaching €163.3 million in 2024, up from €144.6 million in 2023, indicating robust demand for its vaccine offerings. The company also announced total revenue of €169.6 million for 2024, representing a 10% increase compared to the previous year, bolstered by strong sales expectations for the recently FDA-approved Ixchiq vaccine. With projected sales for Ixchiq anticipated to surpass €100 million within three years of its launch and the global market for chikungunya vaccines expected to exceed $500 million annually, Valneva's growth trajectory suggests positive long-term revenue prospects.

Bears say

Valneva SE is projected to reduce its operating cash burn to below €30 million in 2025, down from over €60 million in 2024, indicating a critical need for cost control amidst declining revenue forecasts. The revenue estimate for 2025 has been lowered to €185 million, a significant decline from the previous estimate of €222.5 million, which reflects a challenging market environment and potential difficulties in sales growth. Furthermore, the earnings per share (EPS) estimate for 2025 has been decreased to (€0.65), suggesting continued financial strain as the company adjusts its revenue expectations and sales forecasts for its Ixchiq vaccine.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.